⌘K

Login Start Free

Home/Filings/4/0001127602-23-007327

4//SEC Filing

Eisele Jeffrey 4

Accession 0001127602-23-007327

CIK 0001492422other

View on SEC.gov Company Profile

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 4:34 PM ET

Size

4.4 KB

Accession

0001127602-23-007327

Insider Transaction Report

Form 4

Period: 2023-02-23

Apellis Pharmaceuticals, Inc.APLS

Chief Development Officer

Transactions

Sale
Common Stock
2023-02-23$68.76/sh−1,646$113,179→ 53,883 total

Footnotes (1)

[F1]Sale originated from established 10b5-1 trading plan.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1

filerCIK 0001827326

Filing Metadata

Form type: 4
Filed: Feb 26, 7:00 PM ET
Accepted: Feb 27, 4:34 PM ET
Size: 4.4 KB

View on SEC.gov